Nonpartisan civic infrastructure
AllCiv·Legis1
·

H.R. 4376

BillFederalHouseIn Committee
USTRx Act
About This Bill
Committee
Latest Action · July 9, 2021
Referred to the Subcommittee on Trade.
Congress
117th (2021–2023)
Introduced
July 9, 2021
Cosponsors (0)
None
View PDF ↗

Summary

Highlight any text to annotate
Use Sovereignty To reduce Rx Act or the USTRx Act This bill establishes the role of Chief Pharmaceutical Trade Negotiator within the U.S. Trade Representative (USTR) to conduct trade negotiations, enforce trade agreements relating to U.S. pharmaceutical products, and address acts, policies, or practices of high-income countries that adversely impact the market access of U.S. pharmaceutical manufacturers. The USTR must annually compile a list of high-income countries based on official statistics of the International Bank for Reconstruction and Development of the World Bank. Based on that list, the negotiator must submit a report describing (1) such countries' actions and impacts relating to the pharmaceutical trade, and (2) the current status of any responsive actions taken by the United States.

Take Action

Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.